Jubilant Ingrevia Ltd logo

Jubilant Ingrevia Ltd

JUBLINGREA NSE

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

AI Verdict: HOLD Confidence: 5%

Jubilant Ingrevia trades at a PE of 38.9x with a modest 3-year ROE of just 8%, suggesting the stock is priced for growth that hasn't consistently materialized. While 83% analyst buy ratings and improving working capital (22 days) are encouraging, declining promoter holding (-6.25% over 3 years) and negative 3-year sales CAGR of -3% warrant caution at current valuations.

Key Fundamentals

MicrocapSpecialty ChemicalsChemicals
Market Cap
₹10,035 Cr
Volatility
Moderate
P/E Ratio
35.65
EBITDA
₹511 Cr
Return on Equity
6.68%
Debt to Equity
0.27
Book Value
₹196.28
EPS
₹10.93
52W High
₹851.8
52W Low
₹537.3

Technical Indicators

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 29.6%
  • Company's working capital requirements have reduced from 29.4 days to 22.0 days

Weaknesses

4
  • Stock is trading at 3.22 times its book value
  • Company has a low return on equity of 8.48% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -6.25%

Growth Rate

Revenue Growth
3.07% ↘
Net Income Growth
13.66% ↘
Cash Flow Change
18.17% ↗
ROE
28.44% ↘
ROCE
18.41% ↘
EBITDA Margin (Avg.)
-11.88% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 24d ago
HOLD
Risk medium

Jubilant Ingrevia trades at a PE of 38.9x with a modest 3-year ROE of just 8%, suggesting the stock is priced for growth that hasn't consistently materialized. While 83% analyst buy ratings and improving working capital (22 days) are encouraging, declining promoter holding (-6.25% over 3 years) and negative 3-year sales CAGR of -3% warrant caution at current valuations.

Bull Case 7
  • Strong analyst consensus with 83.33% buy ratings (5 out of 6 analysts recommend buy)
  • Working capital efficiency improved significantly from 29.4 days to 22.0 days, indicating better cash conversion
  • TTM profit growth of 14% shows earnings recovery momentum
  • Healthy dividend payout ratio of 29.6% demonstrates shareholder-friendly capital allocation
  • 5-year compounded profit growth of 35% reflects strong long-term earnings trajectory
  • 5-year compounded sales growth of 45% indicates successful business scaling over the medium term
  • 3-year stock CAGR of 18% has delivered meaningful wealth creation for patient investors
Bear Case 8
  • 3-year ROE of only 8% is subpar for a stock trading at 3.46x book value, implying poor capital efficiency relative to valuation
  • PE ratio of 38.9x is elevated for a commodities sector company with inconsistent growth
  • Promoter holding has declined by 6.25% over 3 years, signaling potential lack of insider confidence
  • 3-year compounded sales CAGR is negative at -3%, indicating revenue contraction in recent years
  • 3-year compounded profit CAGR is negative at -2%, showing earnings have not grown over the medium term
  • Stock has delivered negative 1-year return of -8%, underperforming broader markets
  • Dividend yield of only 0.37% offers minimal income cushion for investors at current price
  • Company might be capitalizing interest costs, potentially flattering reported profitability

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 25d ago
Headwinds 2
  • ₹19.87 cr tax order received May 21

    Assessment order for AY 2023-24 with transfer pricing adjustments of ₹19.87 crore. Company plans to appeal.

  • GST demand on Gajraula unit May 6

    Appeal order confirmed GST demand of ₹1.02 crore plus equal penalty and interest for FY 2017-18.

Positives 4
  • Targets 3X revenue by FY30 May 27

    Long-term strategy targets 3X revenue and 4X EBITDA by FY30, backed by 100+ CDMO opportunities worth ₹3,500 crore and FY27 capex guidance of ₹400-500 crore.

  • Highest quarterly revenue in 14 quarters May 30

    Q4FY26 revenue hit ₹1,179 crore with EBITDA up 11% YoY to ₹172 crore and PAT up 17% to ₹86 crore.

  • 250% dividend recommended for FY26 May 26

    Final dividend of ₹2.50 per share recommended, taking total FY26 payout to ₹5 per share. Record date July 24, 2026.

  • Bharuch CDMO plant commissioned May 30

    New CDMO facility at Bharuch commissioned, supporting the company's specialty chemicals and nutrition growth strategy.

Neutral 2
  • Singapore investor meet in June May 30

    Management to attend Kotak India Corporate Day in Singapore on June 9-10, 2026. Discussions based on publicly available information only.

  • Q4FY26 concall transcript released May 30

    Earnings call transcript posted on website covering Q4 and full-year FY26 results and strategic outlook.

TL;DR: Jubilant Ingrevia delivered strong Q4FY26 results with record quarterly revenue and double-digit profit growth, while laying out an ambitious FY30 roadmap anchored by CDMO expansion. Tax-related headwinds are minor (combined ~₹21 crore) and likely manageable. The trend is clearly improving with commissioning of the Bharuch plant and 20%+ annual EBITDA growth guidance providing near-term catalysts.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
1,145
1,075
1,020
966
1,074
1,024
1,045
1,057
1,051
1,038
1,121
1,051
1,179
Expenses
1,043
958
902
871
983
915
921
918
905
896
985
924
1,016
Operating Profit
102
117
118
96
91
110
124
138
147
142
135
126
163
OPM %
9%
11%
12%
10%
8%
11%
12%
13%
14%
14%
12%
12%
14%
Other Income
9
8
9
9
10
10
10
9
8
11
11
-4
9
Interest
6
11
13
15
14
14
15
12
14
13
12
12
12
Depreciation
30
32
34
34
36
39
40
40
39
41
41
45
48
PBT
76
81
80
55
51
66
80
96
102
100
93
65
112
Tax %
31%
29%
28%
30%
43%
26%
26%
27%
27%
25%
25%
28%
23%
Net Profit
52
58
57
39
29
49
59
69
74
75
69
47
86
EPS in Rs
3.28
3.62
3.61
2.42
1.84
3.06
3.7
4.36
4.65
4.71
4.36
2.94
5.43
Figures in ₹ Crores

Profit & Loss

  Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
0
684
4,949
4,773
4,136
4,178
4,388
Expenses
0
567
4,108
4,224
3,708
3,658
3,821
Operating Profit
0
117
841
549
427
519
567
OPM %
—
17%
17%
11%
10%
12%
13%
Other Income
0
-10
22
32
29
38
27
Interest
0
7
31
22
53
56
49
Depreciation
0
22
123
122
136
158
175
PBT
0
77
709
437
268
344
370
Tax %
0%
30%
33%
30%
32%
27%
25%
Net Profit
0
54
477
308
183
251
278
EPS in Rs
-3.4
3.41
29.93
19.31
11.48
15.77
17.45
Div. Payout %
0%
10%
17%
26%
43%
31%
14%
Figures in ₹ Crores

Balance Sheet

  Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.05
16
16
16
16
16
16
Reserves
0
1,907
2,417
2,650
2,722
2,911
3,110
Borrowings
0
556
238
407
740
764
792
Other Liabilities
0
888
1,111
1,176
1,241
1,324
1,566
Total Liabilities
0
3,366
3,782
4,249
4,719
5,015
5,484
Fixed Assets
0
1,805
1,798
1,846
2,539
2,581
3,183
CWIP
0
65
174
525
331
525
154
Investments
0
50
6
8
15
37
33
Other Assets
0
1,446
1,804
1,870
1,834
1,872
2,113
Total Assets
0
3,366
3,782
4,249
4,719
5,015
5,484
Figures in ₹ Crores

Cash Flow

  Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
112
453
462
430
508
524
Investing
0
33
-71
-469
-568
-389
-276
Financing
0
-72
-418
42
144
-129
-155
Net Cash Flow
0
73
-36
35
6
-9
93
Free Cash Flow
0
85
225
-16
-136
156
235
CFO/OP
0
106
69
98
111
113
111
Figures in ₹ Crores

Ratios

  Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
251
43
39
50
53
65
Inventory Days
—
601
119
146
160
163
140
Days Payable
—
685
104
113
131
141
150
Cash Conversion Cycle
—
167
58
72
80
75
55
Working Capital Days
—
220
49
42
37
29
22
ROCE %
—
8%
29%
16%
10%
11%
11%

Shareholding Pattern

As of Mar 2026
Promoters 45.22%
DIIs 24.76%
Public 17.44%
FIIs 6.49%
Others 6.06%
Government 0.02%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
50.68%
50.92%
50.92%
51.03%
51.10%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
51.47%
45.22%
45.22%
45.22%
45.22%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
6.35%
6.58%
6.55%
7.22%
6.89%
7.12%
6.96%
5.96%
6.15%
6.49%
DIIs
0.83%
0.96%
0.32%
0.14%
0.15%
0.17%
1.38%
4.90%
5.98%
6.73%
8.21%
11.18%
13.61%
14.09%
15.47%
15.99%
15.92%
21.80%
23.04%
24.00%
24.76%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.02%
0.02%
0.02%
Public
16.76%
21.30%
27.18%
26.23%
27.31%
27.61%
26.71%
25.75%
25.72%
26.13%
24.11%
22.74%
20.63%
20.57%
19.47%
19.17%
19.13%
19.41%
19.20%
18.29%
17.44%
Others
31.74%
26.82%
21.58%
22.60%
21.43%
20.75%
20.44%
17.87%
16.83%
15.66%
16.20%
8.26%
7.71%
7.32%
6.36%
6.47%
6.36%
6.60%
6.56%
6.32%
6.06%
No. of Shareholders
60,038
95,235
1,49,939
1,81,847
1,91,477
1,93,858
1,95,704
1,86,895
1,85,062
1,86,294
1,73,533
1,62,202
1,50,388
1,42,736
1,25,367
1,24,830
1,20,406
1,23,748
1,25,749
1,17,529
1,12,696

Documents

Frequently Asked Questions about Jubilant Ingrevia Ltd

What does Jubilant Ingrevia Ltd do?
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality sta...
Where is Jubilant Ingrevia Ltd (JUBLINGREA) listed?
Jubilant Ingrevia Ltd is listed on the Indian stock exchanges. It is listed on NSE: JUBLINGREA and BSE: 543271. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jubilant Ingrevia Ltd belong to?
Jubilant Ingrevia Ltd operates in the Commodities sector within the Chemicals & Petrochemicals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jubilant Ingrevia Ltd?
Jubilant Ingrevia Ltd has a market capitalisation of approximately ₹10034.71 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Jubilant Ingrevia Ltd?
The Price-to-Earnings (PE) ratio of Jubilant Ingrevia Ltd is 35.65. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jubilant Ingrevia Ltd?
Over the past 52 weeks, Jubilant Ingrevia Ltd has traded between a low of ₹537.3 and a high of ₹851.8. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jubilant Ingrevia Ltd pay dividends?
Yes, Jubilant Ingrevia Ltd has a dividend yield of 0.79%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jubilant Ingrevia Ltd?
Jubilant Ingrevia Ltd has a Return on Equity (ROE) of 6.68%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jubilant Ingrevia Ltd on Tapetide?
On Tapetide, you can view Jubilant Ingrevia Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Website jubilantingrevia.com
Listed 2021-03-19
Face Value ₹ 1
Issued Size 15,92,81,139

Explore More

More in Commodities → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List